Longitudinal pathways of exclusive and polytobacco cigar use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1-3 (2013-2016).
non-cigarette tobacco products
prevention
surveillance and monitoring
Journal
Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
13
01
2020
revised:
22
01
2020
accepted:
27
01
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
3
6
2021
Statut:
ppublish
Résumé
The goal of this study is to examine the cross-sectional prevalence of use and 3-year longitudinal pathways of cigar use in US youth (12-17 years), young adults (18-24 years), and adults 25+ (25 years or older). Data were drawn from the first three waves (2013-2016) of the Population Assessment of Tobacco and Health Study, a nationally representative, longitudinal cohort study of US youth and adults. Respondents with data at all three waves (youth, n=11 046; young adults, n=6478; adults 25+, n=17 188) were included in longitudinal analyses. Weighted cross-sectional prevalence of past 30-day (P30D) use was stable for adults 25+ (~6%), but decreased in youth (Wave 1 (W1) to Wave 3 (W3)=2.5% to 1.2%) and young adults (W1 to W3=15.7% to 14.0%). Among W1 P30D cigar users, over 50% discontinued cigar use (irrespective of other tobacco use) by Wave 2 (W2) or W3. Across age groups, over 70% of W1 P30D cigar users also indicated P30D use of another tobacco product, predominantly cigar polytobacco use with cigarettes. Discontinuing all tobacco use by W2 or W3 was greater in adult exclusive P30D cigar users compared with polytobacco cigar users. Although the majority of P30D cigar users discontinued use by W3, adult polytobacco users of cigars were less likely to discontinue all tobacco use than were exclusive cigar users. Tracking patterns of cigar use will allow further assessment of the population health impact of cigars.
Identifiants
pubmed: 32321850
pii: tobaccocontrol-2020-055624
doi: 10.1136/tobaccocontrol-2020-055624
pmc: PMC7523336
mid: NIHMS1604098
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
s163-s169Subventions
Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: WMC reports long-term stock holdings in General Electric Company, 3M Company, and Pfizer Incorporated, unrelated to this manuscript. No financial disclosures were reported by the other authors of this paper.
Références
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):597-603
pubmed: 28617771
Tob Regul Sci. 2017 Apr;3(Suppl 1):S72-S83
pubmed: 28966952
Tob Regul Sci. 2017 Apr;3(2 Suppl 1):S48-S58
pubmed: 29085867
Nicotine Tob Res. 2018 Nov 15;20(12):1457-1466
pubmed: 29059423
Public Health Rep. 2006 Mar-Apr;121(2):116-9
pubmed: 16528942
Am J Health Behav. 2013 May;37(3):325-33
pubmed: 23985179
Am J Prev Med. 2014 Aug;47(2 Suppl 1):S76-86
pubmed: 25044199
Tob Control. 2020 May;29(Suppl 3):s139-s146
pubmed: 32321847
Tob Control. 2020 May;29(Suppl 3):s191-s202
pubmed: 32321853
Tob Control. 2020 May;29(Suppl 3):s216-s226
pubmed: 32321855
Tob Control. 2020 May;29(Suppl 3):s178-s190
pubmed: 32321852
Tob Control. 2020 May;29(Suppl 3):s203-s215
pubmed: 32321854
Nicotine Tob Res. 2015 Dec;17(12):1473-81
pubmed: 25634932
Fed Regist. 2016 May 10;81(90):28973-9106
pubmed: 27192730
Tob Control. 2020 May;29(Suppl 3):s163-s169
pubmed: 32321850
MMWR Morb Mortal Wkly Rep. 2014 Aug 1;63(30):650-4
pubmed: 25078654
BMC Public Health. 2016 Aug 18;16(1):814
pubmed: 27538489
Prev Med. 2014 May;62:14-9
pubmed: 24440684
Tob Control. 2020 May;29(Suppl 3):s155-s162
pubmed: 32321849
Nicotine Tob Res. 2013 May;15(5):925-31
pubmed: 23072873
Tob Control. 2019 Nov;28(6):663-668
pubmed: 30297373
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
N Engl J Med. 2017 Jan 26;376(4):342-353
pubmed: 28121512
Tob Control. 2020 May;29(Suppl 3):s170-s177
pubmed: 32321851
Tob Control. 2020 May;29(Suppl 3):s147-s154
pubmed: 32321848
J Adolesc Health. 2003 Dec;33(6):436-57
pubmed: 14642706
BMC Public Health. 2015 Apr 24;15:390
pubmed: 25907101